CA
NZ
UK
AU
IND
US
• The Ebola PCR development pipeline and Mexico CO-Dx PCR Pro distribution agreement attracted renewed investor attention.
• The FDA clinical hold on ARD-101 for Prader-Willi syndrome, placed in May 2026, remains in effect.
• ABSI closed near $10.07 on June 24, 2026, its best single-session gain on record at approximately 36%.
• No material company-specific announcement was identified as a catalyst for the session.
• Wellgistics Health operates in healthcare distribution and pharmacy services with limited institutional ownership.
• Shares closed at $3.85, down more than 8% on June 24, with no company-specific catalyst identified.
• Shares closed at $2.30, down more than 21% on June 24, approaching a 52-week low of $4.20 established just days prior.
• Shares closed at $86.24, down more than 11% on June 24, pulling back from a 52-week high of $102.06.
• The stock has lost approximately 87% over the prior twelve months.
• Shares closed at $5.87, down more than 16% on June 24, with no identifiable company-specific trigger.
Please wait processing your request...